The newest ones are a phase II trial (NCT04231864) to evaluate epacadosat plus durvalumab, a anti-PD-L1 antibody, for treatment of advanced Epstein-Barr virus (EBV) positive nasopharyngeal carcinoma (NPC) and a phase III trial (NCT03661320) to assess IDO1 inhibitor (BMS-986205) in combination with nivolumab and chemotherapy (gemcitabine and cisplatin) as neoadjuvant treatment in patients with muscle-invasive bladder cancer. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.